Hyperprolactinemia Associated with Chronic Renal Failure in the Rat

Summary

Patients with CRF exhibit hyperprolactinemia and resistance to the prolactin-suppressive effects of dopamine. In order to explore the pathogenetic mechanisms involved, an animal model of CRF was developed in the adult male rat bearing an indwelling right atrial catheter by performing a two stage 5/6 nephrectomy (NX). Following NX, serum creatinine levels rose to a value of 1.36 ± 0.2 mg/dl at 8 weeks as compared to sham-operated controls (0.31 ± 0.1, P < 0.01). There was a parallel increase in plasma prolactin levels in NX animals with values significantly greater than in controls by 8 weeks (49 ± 11 vs 17 ± 2 ng/ml, P < 0.02). At 8 weeks, the plasma prolactin responses to metoclopramide (500 ug/kg, iv)were similar in unanesthetized NX and sham-operated control animals. The prolactin-suppressive effects of an iv dopamine infusion (6 ug/kg/min × 30 min) was also similar in the two groups (46 ± 8% vs 40 ± 10% suppression). The responses of lactotrophs in vitro were compared in NX and control animals at 8 weeks. Basal prolactin release during 4 h was similar in the two groups as were the suppressive responses to dopamine and bromocriptine. The results indicate that the rat with CRF, like human develops hyperprolactinemia. In contrast to the human, however, responses to dopaminergic agonists and antagonists in vivo and in vitro are unimpaired, indicating that hyperprolactinemia in rats with CRF occurs on a non-dopaminergic basis.

Key-Words

Hyperprolactinemia - Chronic Renal Failure - Dopamine - Metoclopramide - Bromocriptine